References
- Stampfer M. J., Colditz G. A., Willett W. C., et al. Postmenopausal oestrogen therapy and cardiovascular disease. Ten year follow-up from the nurses' health study. N. Engl. J. Med. 1991; 325: 756–62
- Grady D., Rubin S. M., Petitti D. B., et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann. Int. Med. 1992; 117: 1016–37
- Henderson B. E., Paganini-Hill A., Ross R. K. Decreased mortality in users of oestrogen replacement therapy. Arch. Intern. Med. 1991; 151: 75–8
- Adams M. R., Kaplan J. R., Manuck S. B., et al. Inhibition of coronary artery atherosclerosis by 17β-oestradiol in ovariectomized monkeys. Lack of an effect of adding progesterone. Arteriosclerosis 1990; 10: 1051–7
- Wagner J. D., Clarkson T. B., St Clair R. W., Schwenke D. C., Shively C. A., Adams M. R. Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. J. Clin. Invest. 1991; 88: 1995–2002
- Gevers Leuven J. A. Sex steroids and lipoprotein metabolism. Pharmac. Ther. 1994; 64: 99–126
- Gevers Leuven J. A., Mooren M. J., van der Buytenhek R. The effect of medrogestone on lipids and lipoproteins in postmenopausal women using conjugated oestrogens: an open randomized comparative study. Fertil. Steril. 1995; 64: 525–31
- Brussaard H. E., Gevers Leuven J. A., Krans H. M.J., Meyer P., Buytenhek R., Kluft C. Non-esterified fatty acids are related with hypofibrinolysis in type 2 diabetes mellitus. Fibrinolysis 1994; 8: 25–7
- Collins P., Rosano G. M. C., Sarrel P. M. 17-β estradiol attenuates acetyl choline induced coronary constriction in women but not in men with coronary artery disease. Circulation 1995; 92: 24–30
- Rosano C., Sarrel P. M., Poole-Wilson P. A., Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 1993; 342: 133–6
- Barrett-Connor E. Heart disease in women. Fertil. Steril. 1994; 62: 127S–32S
- DeStefano F., Ford E. S., Newman J., et al. Risk factors for coronary heart disease mortality among persons with diabetes. Ann. Epidemiol. 1993; 3: 27–34
- Hemminki E., Sihvo S. A review of postmenopausal hormone therapy recommendations: a potential for selection bias. Obstet. Gynecol. 1993; 82: 1021–8
- Blann A. D., Taberner D. A. A reliable marker of endothelial cell dysfunction: does it exist. Br. J. Haematol. 1995; 90: 244–8
- Peters J. H., Maunder R. J., Woolf A. D., Cochrane C. G., Ginsberg M. H. Elevated plasma levels of ED1 + (‘cellular’) fibronectin in patients with vascular injury. J. Lab. Clin. Med. 1989; 113: 586–97
- Carnemolla B., Borsi L., Zardi L., Owens R. J., Baralle F. E. Localization of the cellular-fibronectin-specific epitope recognized by the monoclonal antibody IST-9 using fusion proteins expressed in E. coli. FEBS Lett. 1987; 215: 260–73
- Tranquille N., Emeis J. J. The simultaneous acute release of tissue-type plasminogen activator and von Willebrand factor in the perfused rat hindleg region. Thromb. Haemostas. 1990; 63: 454–8
- Amiral J., Adam M., Mimilla F., Larrivaz I., Chambrette B., Boffa M. C. Design and validation of a new immunoassay for soluble forms of thrombomodulin and studies in plasma. Hybridoma 1994; 13: 205–13
- Takahashi H., Ito S., Hanano M., Wada K., Niwano H., Seki Y., Shibata A. Circulating thrombomodulin as a novel endothelial cell marker: comparison of its behaviour with von Willebrand factor and tissue-type plasminogen activator. Am. J. Haematol. 1992; 41: 32–9
- Kooistra T., Lansink M., van Kesteren P., Koolwijk P., Toet K., Peters E., Hegeman R., Emeis J., Stehouwer C., Gooren L., van Hinsbergh V. W.M. Effects of steroid hormones on the secretion of haemostatic factors in and angiogenic properties of human vascular endothelial cells. Am. J. Obstet. Gynecol. 1996, in press
- Nilsson T. K., Boman K., Bjerle P., Hallmans G., Hellstein G. von Willebrand factor and fibrinolytic variables are differently affected in the insulin resistance syndrome. J. Int. Med. 1994; 235: 419–23